Please note that this website is no longer being maintained. For all current information and registration please refer to GenQA.

Schemes

Molecular Pathology

UK NEQAS for Molecular Genetics and UK NEQAS for Immunocytochemistry and In-Situ Hybridisation are delighted to offer EQA for Molecular Pathology testing in solid tumours. Molecular Pathology testing often involves a collaboration between pathology and molecular genetics laboratories and therefore our collaboration reflects the nature of this interaction. The Molecular Pathology EQAs are provided by UK NEQAS for Molecular Genetics and UK NEQAS for Immunocytochemistry and In-Situ Hybridisation inputs via the Expert Advisory Group.

Lung cancer EQA 2017-18 (open to all laboratories)

This disease based EQA scheme has been expanded to included gene panel testing. Participants are required to perform EGFR gene testing and report their results according to the clinical cases supplied. This result will be assessed and performance criteria applied. Testing for the ALK gene rearrangement is also available and laboratories can test by FISH, IHC or RT-PCR. Please inform the Scheme when registering which technique your laboratory will use so the appropriate samples can be supplied. If an ALK gene rearrangement test is reported then the results will be assessed and performance criteria applied.

The samples will also be validated for mutations in the KRAS, BRAF and PIK3CA genes. Assessment of these gene test results will be on a pilot basis and feedback comments will be given to laboratories.

Four/five samples will be distributed per EQA run. There will be two EQA runs during the 12 month period (April 2017 to March 2018).

Run 1 - April 2017 distribution of five EQA samples for testing.

Run 2 - October 2017 distribution of four EQA samples for testing.

Following the success of the first additional lung biomarkers pilot EQA scheme, another pilot scheme will be provided during 2017. This will consist of one distribution with samples being sent in October, 2017. Laboratories will be supplied with formalin fixed paraffin embedded samples for ROS1 and RET testing by RT-PCR of FISH and MET testing by FISH. Reports will be assessed for genotyping accuracy. The fee for this pilot EQA is £220.

 

Colorectal cancer EQA 2017-18 (open to all laboratories)

This disease based EQA scheme has been expanded to included gene panel testing. Participants are required to perform KRAS and NRAS gene testing and report their results according to the clinical cases supplied. These results will be assessed and performance criteria applied.

The samples will also be validated for mutations in the BRAF and PIK3CA genes. Assessment of these gene test results will be on a pilot basis and feedback comments will be given to laboratories.

Four/five samples will be distributed per EQA run. There will be two EQA runs during the 12 month period (April 2017 to March 2018).

Run 1 - April 2017 distribution of five EQA samples for testing.

Run 2 - October 2017 distribution of four EQA samples for testing.

 

Melanoma testing EQA 2017-18 (open to all laboratories)

This disease based EQA scheme has been expanded to included gene panel testing. Participants are required to perform BRAF gene testing and report their results according to the clinical cases supplied. This result will be assessed and performance criteria applied.

The samples will also be validated for mutations in the NRAS and KIT genes. Assessment of these gene test results will be on a pilot basis and feedback comments will be given to laboratories.

Four/five samples will be distributed per EQA run. There will be two EQA runs during the 12 month period (April 2017 to March 2018).

Run 1 - April 2017 distribution of five EQA samples for testing.

Run 2 - October 2017 distribution of four EQA samples for testing. 

 

GIST EQA 2017 (open to all laboratories)

Over the past few years there have been significant advances in the management of gastro-intestinal stromal tumours (GISTs) and molecular testing of and is now becoming widespread. Participants are required to test tumour samples for changes in the KIT and PDGFRA genes and report their genotyping results. These results will be assessed and performance criteria applied.

Three samples will be distributed for the 2017 GIST EQA as one EQA run in September 2017.

 

SARCOMA TESTING EQA 2017 (open to all laboratories)

Over the past few years pilot EQAs has been provided for RT-PCR testing  and FISH testing for the presence of translocations in sarcomas.W eare pleased to annouce the provision of a full EQA scheme will applied performnace criteria for 2017. The EQA will run during September 2017 and will be offered in collaboration with CEQAS.

 

Scheme fees for 2017 -click here

 

 

Microsatellite instability testing EQA 2017 (open to all laboratories)

This EQA has been expanded from previous EQ runs. As many laboratories routinely test formalin fixed paraffin embedded (FFPE) tissue for MSI, this EQA will incorporate the testing of DNA samples or FFPE tissue samples also also be extended to incorporate subsequent testing e.g. MLH1 promoter tesitng and BRAF mutation anlaysis. Please see Genotyping only scheme for further details.

 

Molecular tissue identification pilot 2017 (open to all laboratories)

Laboratories test tissue samples using molecular fingerprinting assays for a variety of reasons e.g. confirmation of origin of tissue, sample switch detection, sample mislabelling. To provide laboratories with assurance of the quality of this testing and accuracy of data analysis, a second pilot EQA run will be offered. Three EQA cases will be supplied. Participants will be required to extract DNA from FFPE tissue and perform molecular identification assays. Clinical case scenarios will be provided to allow interpretation of the result.

Samples will be distributed in September 2017.

 

BRCA testing in ovarian cancer (somatic and germline) pilot EQA 2017

UK NEQAS for Molecular Genetics in collaboration with EMQN are proud to provide a new pilot EQA scheme for ovarian cancer. This is supported by an educational grant from Astra Zeneca.
The 2017 pilot scheme willenable participation for germline and/or somatic testing for BRCA1 and BRCA2 variants. Full details will be relased as they have been finalised.

 

Tissue-i (open to all laboratories)

Molecular pathology testing of solid tumour relies on the pathological review of H&E stained tissue sections to annotate tumour regions for enrichment by macrodissection. This ensures sample quality, sufficiency of tumour DNA for analysis and ultimately the precision of the molecular test result. For the use of sensitive molecular techniques this is critical to deliver high quality testing and allow accurate interpretation of the sequence variants detected. It is known that the annotation of tumour and estimation of neoplastic nuclei can be highly variable thus there is a need to measure the degree of variation between laboratories and standardise approaches to tumour annotation and analysis to promote high quality molecular pathology testing.

This module covers a range of tissue types (breast cancer, colorectal cancer, lung cancer, melanoma, ovarian cancer and prostate cancer). Participants can select which tissue type they wish to assess. They will be required to mark the regions of tumour they deem appropriate for macrodissection for molecular testing, drawing the boundary using the online EQA module. An estimation of the cellularity and percentage of neoplastic nuclei across the slide image and within the annotated region will be requested.

This online competency tool has been designed to provide a source of external review, benchmarking with peers and evidence continual professional development in the field of molecular pathology tissue assessment for the individual.

Registration will enable access to all five tissue types to up to 3 users for an EQA run. This registration will cost £480. Additional users can be added at a reduced fee of £100 per user. Please contact the Scheme if you would like to include additional users. Please be assured that the Scheme is aware of the financial constraints on laboratories and therefore has endeavoured to keep fees as low as possible to enable maximum participation across laboratories.

Full details can be accessed here - Tissue-i flyer 2017.pdf

Laboratories linked to a NHS Genomic Medicine Centre do not need to register for participation in this assessment. You will be contacted by the Scheme regarding participation covered by NHS England.